McClellan slates FDA adverse event reporting

1 April 2007

Mark McClellan, the former US Food and Drug Administration Commissioner who retired last year as the Administrator of the Centers for Medicare and Medicaid Services (CMS, Marketletters passim), has criticized the lack of effectiveness of the FDA's adverse event reporting system.

Speaking to the BioCentury, a specialist biotechnology industry newsletter, Mr McClellan said: "when you have an adverse event reporting system that only captures about 10% of cases, that does it with variable time lags, and with inconsistently collected information, and isn't linked to an adequate infrastructure at the FDA to analyze the information, no wonder there is real public concern." The former FDA chief suggested that the agency should pool data from both public and private databases to improve its ability to monitor adverse events.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight